Amgen's skin cancer drug hits main goal in late-stage trial

03/20/2013 | Reuters

Sixteen percent of patients who took Amgen's experimental advanced melanoma drug talimogene laherparepvec experienced at least partial tumor shrinkage for six months, compared with 2% of patients who received subcutaneous granulocyte-macrophage colony-stimulating factor, preliminary data from a late-stage trial showed. A detailed look at the study is set for release at a medical meeting this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA